Esophageal cancer treatment costs by phase of care and treatment modality, 2000‐2013

Tramontano, Angela C.; Chen, Yufan; Watson, Tina R.; Eckel, Andrew; Hur, Chin; Kong, Chung Yin

doi:10.1002/cam4.2451

Cited by 26 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We based our cost estimation methods on previous studies. [20][21][22][23] We defined treatment modalities for patients with stages I-III CRC based on treatment(s) initiated two months prior to cancer diagnosis through six months after diagnosis. The two months prior to diagnosis were included to account for any treatment given to a symptomatic cancer patient who had not yet been diagnosed, as well as possible errors in dates recorded in the claims.…”

Section: Cost-estimation Methodsmentioning

confidence: 99%

Racial/ethnic disparities in colorectal cancer treatment utilization and phase-specific costs, 2000-2014

Tramontano¹,

Chen²,

Watson³

et al. 2020

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background Our study analyzed disparities in utilization and phase-specific costs of care among older colorectal cancer patients in the United States. We also estimated the phase-specific costs by cancer type, stage at diagnosis, and treatment modality. Methods We used the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to identify patients aged 66 or older diagnosed with colon or rectal cancer between 2000-2013, with follow-up to death or December 31, 2014. We divided the patient's experience into separate phases of care: staging or surgery, initial, continuing, and terminal. We calculated total, cancer-attributable, and patient-liability costs. We fit logistic regression models to determine predictors of treatment receipt and fit linear regression models to determine relative costs. All costs are reported in 2019 US dollars. Results Our cohort included 90,023 colon cancer patients and 25,581 rectal cancer patients. After controlling for patient and clinical characteristics, Non-Hispanic Blacks were less likely to receive treatment but were more likely to have higher cancer-attributable costs within different phases of care. Overall, in both the colon and rectal cancer cohorts, mean monthly cost estimates were highest in the terminal phase, next highest in the staging phase, decreased in the initial phase, and were lowest in the continuing phase. Conclusions Racial/ethnic disparities in treatment utilization and costs persist among colorectal cancer patients. Additionally, colorectal cancer costs are substantial and vary widely among stages and treatment modalities. This study provides information regarding cost and treatment

show abstract

Section: Cost-estimation Methodsmentioning

confidence: 99%

Racial/ethnic disparities in colorectal cancer treatment utilization and phase-specific costs, 2000-2014

Tramontano¹,

Chen²,

Watson³

et al. 2020

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…For example, Angela and her groups have made a large number of statistics on the cost of patients with esophageal cancer with different treatment methods for a long time. For example, the average cost of radiotherapy for stage III patients is $7530, and the average cost of chemoradiotherapy is $11460 [48], if we can predict how well a patient will respond to treatments, it will save individuals and Medicare a lot of money.…”

Section: Discussionmentioning

confidence: 99%

Using 18F-FDG PET/CT to Predict Esophageal Cancer Survival: A Meta-Analysis

Wang¹,

Song²,

S³

2021

austinjradiol

View full text Add to dashboard Cite

Purpose: This study aimed to explore whether metabolic responses to 18F-fluorodeoxyglucose positron emission tomography/computed tomography collected before, during, or after the treatment can predict the long-term survival rate of patients with esophageal cancer. Patients and Methods: We searched for the following indices in articles listed in English and Chinese literature databases: the maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), Metabolic Tumor Volume (MTV), and Total Lesion Glycolysis (TLG). If their values exceeded the thresholds, we defined them as responders; if they did not, we defined them as non-responders. We then performed a meta-analysis by extracting the Hazard Ratio (HR) and 95% confidence interval (95% CI) from each report to predict whether the status of responder or non-responder had an impact on prognosis. Results: We identified 34 articles with a combined sample size of 2794 patients. HRs and 95% CIs were measured as follows: SUVmax = 1.15 (0.98- 1.35), MTV = 3.45 (0.78-15.25), TLG = 1.04 (1.02-1.07), and SUVmean = 1.85 (1.33-2.57) (before treatment); ΔSUVmax = 1.22 (1.06-1.39), Δ MTV = 1.07 (0.54- 2.15), and ΔTLG = 1.09 (0.59-2.02) (during treatment); and SUVmax = 1.13 (1.05- 1.22) and TLG = 1.05 (1.02-1.09) (after treatment). The results showed that the overall survival of the patients with low SUV (MTV, TLG) values was significantly higher than that of the patients with high SUV (MTV, TLG) values. Conclusions: This meta-analysis shows that the prognoses of patients with PET metabolic responses are significantly better than those of non-responders. Our findings may help inform the clinical treatment and prediction of the prognoses of patients with esophageal cancer.

show abstract

“…In spite of BE surveillance and advances in endoscopy, only about 23.7% of EAC are diagnosed at stage I, 20.7% at stage II, 20.4% stage III, and 34.2% at stage IV disease. 46 Since the majority of patients are diagnosed at later stages with disease spread beyond the esophagus, EET is therapeutic in only a small fraction of patients presenting with EAC.…”

Section: Limitations Of Eetmentioning

confidence: 99%

Indications, contraindications and limitations of endoscopic therapy for Barrett’s esophagus and early esophageal adenocarcinoma

Rouphael

Kumar

Sanaka

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Endoscopic eradication therapy (EET) has revolutionized management of Barrett’s esophagus (BE)-associated neoplasia, traditionally treated by esophagectomy, which carries very high mortality and morbidity. EET, usually performed in the outpatient setting, has a safe risk profile. It is indicated in patients with BE with high-grade dysplasia and intramucosal cancer, confirmed, and persistent low-grade dysplasia, and in highly selected cases of non-dysplastic BE and submucosal cancers. Multiple EET modalities are available and can be categorized into two groups: ablation therapies and resection techniques with resection techniques usually reserved for nodular/raised lesions or lesions with suspected neoplasia. Patients usually require multiple ablation sessions with a goal of achieving complete eradication of metaplasia. Despite very good results, EET has its limitations and is not 100% effective: it targets a small subset of patients along the spectrum of BE and esophageal adenocarcinoma, as most patients with esophageal adenocarcinoma remain asymptomatic until the disease has progressed to advanced stages. Post-ablation surveillance is mandatory, as recurrences are common. An area of concern is buried metaplasia reported to occur following ablation therapy and thought to be from de novo growth of metaplastic tissue underneath the neosquamous epithelium, following ablation. The focus of this review article is to present the indications, contraindications and limitations of EET.

show abstract

Esophageal cancer treatment costs by phase of care and treatment modality, 2000‐2013

Cited by 26 publications

References 30 publications

Racial/ethnic disparities in colorectal cancer treatment utilization and phase-specific costs, 2000-2014

Racial/ethnic disparities in colorectal cancer treatment utilization and phase-specific costs, 2000-2014

Using 18F-FDG PET/CT to Predict Esophageal Cancer Survival: A Meta-Analysis

Indications, contraindications and limitations of endoscopic therapy for Barrett’s esophagus and early esophageal adenocarcinoma

Contact Info

Product

Resources

About